Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.


PURPOSE To evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of mapatumumab, a fully human monoclonal antibody targeting tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with gemcitabine and cisplatin. EXPERIMENTAL DESIGN Patients with advanced solid tumors received gemcitabine 1,250… (More)
DOI: 10.1158/1078-0432.CCR-09-0996

6 Figures and Tables


  • Presentations referencing similar topics